Oppenheimer Maintains Outperform on Ventyx Biosciences, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones maintains an Outperform rating on Ventyx Biosciences (NASDAQ:VTYX) but lowers the price target from $12 to $10.
June 06, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer analyst Jeff Jones maintains an Outperform rating on Ventyx Biosciences but lowers the price target from $12 to $10.
The Outperform rating suggests continued confidence in Ventyx Biosciences' performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100